Trials / Completed
CompletedNCT04883606
A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome
Non-interventional, Multicenter Retrospective Study of the Effectiveness and Safety of Teduglutide (Revestive®) in Short Bowel Syndrome Adult Patients in Spain (T-Rex Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 65 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aims of the study are to assess the safety profile of teduglutide (Revestive®) as well as how many people with Short Bowl Syndrome experience a reduction of parenteral support when treated with teduglutide (Revestive®). This study is about collecting existing data only; participants will not receive teduglutide (Revestive®) as part of this study. No new information will be collected during this study. Only data already available in the hospital records will be reviewed and collected for this study. Participants do not need to visit their doctor in addition to their normal visits.
Conditions
Timeline
- Start date
- 2022-01-26
- Primary completion
- 2023-07-24
- Completion
- 2023-07-24
- First posted
- 2021-05-12
- Last updated
- 2023-08-31
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04883606. Inclusion in this directory is not an endorsement.